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Abstract  49 
Background: Elevated levels of circulating plasma and urine leucine-rich-2-glycoprotein-1 50 
(LRG1) protein has been found in patients with acute appendicitis (AA) and may be useful for 51 
diagnosis. This study aimed to investigate whether combined tests including circulating LRG1 52 
mRNA levels improves the early diagnosis of AA.  53 
Methods: Between December 2011 and October 2012, a prospective study was conducted on 54 
patients aged 18 years or older presenting to the ED with acute abdominal pain (<7 days of 55 
symptom onset). Levels of whole blood LRG1 mRNA levels and plasma LRG1 protein taken 56 
from these patients within 24 hours of arrival (mean 12.4h) were analyzed. The primary outcome 57 
was AA. 58 
Results: Eighty-four patients (40 (47.6%) with AA and 44 (52.4%) without AA; mean age 35 59 
years; 41.6% males) were recruited. Median whole blood LRG1 mRNA and plasma LRG1 levels 60 
were higher in AA patients than in non-AA Of 40 AA patients, 13 (32.5%) were diagnosed as 61 
complicated AA, and had median LRG1 mRNA level higher than in patients with complicated 62 
AA  In ROC analysis of LRG1 mRNA (normalized to GAPDH), LRG1 protein and Alvarado 63 
score for discriminating AA and non-AA, the areas under the curve (AUC) were 0.723, 0.742 64 
and 0.805 respectively. The combination of normalized LRG1 mRNA, LRG1 protein and 65 
Alvarado score demonstrated the largest AUC (0.845). Conclusion: A combination of modified 66 
whole blood LRG1 mRNA levels, serum LRGI protein and Alvarado score at the ED may be useful 67 
to diagnose simple and complicated AA from other causes of abdominal pain..  68 
  69 
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Introduction  70 
Acute appendicitis (AA) is a common life-threatening abdominal emergency, which in 2010, 71 
claimed 34800 deaths worldwide [1].  In the USA simple AA accounts for an average of 1.8 days 72 
in hospital, perforated AA accounts for 5.2 hospital days [2] and the incidence is increasing [3].  73 
AA is commonly diagnosed based on clinical history, physical examination, simple laboratory 74 
tests and imaging [4-7], including the Alvarado score) [8, 9], white cell count or C-reactive 75 
protein [10], urinary 5-hydroxyindoleacetic acid (5-HIAA) [11]), and ultrasonography , CT  and 76 
MRI [12-14] (see Appendix for a summary).  The gold standard is CT imaging but this is not 77 
always available, and its radiation carries some cancer risk especially in the young.  This has led 78 
some to search for alternative pathways for accurately diagnosing AA [7]. 79 
 80 
Circulating biomarkers have the potential to improve the diagnostic accuracy of AA in cases 81 
where utilizing CT or MRI would be inappropriate, delayed or unavailable. Leucine-rich α-2-82 
glycoprotein-1 (LRG1) belongs to the leucine-rich repeat (LRR) family of proteins, many of 83 
which are involved in protein-protein interaction, signal transduction, and cell adhesion [15]. The 84 
biological function of LRG1 is unclear, but recently studies have demonstrated that LRG1 is 85 
expressed during granulocyte differentiation [16] and required for pathological angiogenesis [17].  86 
Using a proteomic approach, LRG1 has recently been identified as a specific marker of AA 87 
[18,19]. High expressions of LRG1 protein have been found in the inflammed appendices of 88 
patients with AA, and increases in its level have been observed in urine and plasma of children 89 
with AA [18-20]. Its concentration correlated with histological severity of appendicitis [19-20]. 90 
A new diagnostic marker of specific LRG1 peptides using selected ion monitoring mass 91 
spectrometry has been developed, and superior diagnostic performance (AUC: 0.98) has been 92 
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demonstrated in the urine of children with AA. However, over 24 hours are required to detect 93 
urine LRG1 using this method, which limits its application in emergency settings. A commercial 94 
ELISA for LRG1 has also become available, and with shorter processing times than mass 95 
spectrometry. However, immunoassay interference resulted in inadequate performance for 96 
clinical use [19-20].   97 
 98 
Although previous studies have studied changes in protein levels, such levels are dependent upon 99 
the upstream expression of LRG1 mRNA which encodes LRG1 protein. Nucleic acids are well 100 
regarded as early markers of acute illness and injury [21-36], and we have previously 101 
demonstrated a potential clinical role for plasma DNA as a prognostic marker in patients with 102 
acute abdominal pain [21].   103 
 104 
In adult patients aged over 18 years presenting to an emergency department with acute 105 
abdominal pain, what is the add-on diagnostic and risk-stratification value of circulating levels of 106 
LRG1 and LRG1 mRNA in patients with AA?  We hypothesise that there are significant 107 
differences in levels of circulating LRG1 and LRG1 mRNA between patients with AA, and those 108 
patients without AA, and that there will be a positive correlation between circulating levels and 109 
the severity of appendicitis. Thus the aims of this study were (1) to investigate the diagnostic 110 
value of plasma LRG1 and whole blood LRG1 mRNA level in patients with suspected AA, and 111 
(2) to elucidate the correlation between whole blood LRG1 mRNA and histological severity of 112 
appendicitis, and (3) to investigate early temporal relationships in circulating LRGI and LRGI 113 
mRNA in patients with acute abdominal pain. This may enable the development of novel protein 114 
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and mRNA-based blood markers or combinations to improve the diagnostic accuracy of simple 115 
and complicated AA.  116 
 117 
Materials and methods 118 
Subjects and data collections  119 
Approval was obtained from Institutional Review Board of the Chinese University of Hong 120 
Kong to conduct this prospective study (CREC 2015.710). Written consent was obtained either 121 
from the patient or a relative in all cases.  122 
 123 
Eligible patients included those aged 18 years and above, presenting to the Emergency 124 
Department of the Prince of Wales Hospital, Hong Kong, with abdominal pain of less than 7 125 
days duration.  Thirty-one healthy volunteers matched for mean age and sex were recruited. Final 126 
diagnosis was determined by the presence or absence of appendicitis on gross and histologic 127 
examination.  128 
 129 
Inclusion and exclusion criteria 130 
Patients aged 18 or above presenting to the ED with acute abdominal pain of likely surgical 131 
cause within 7 days of symptom onset were recruited. Patients were excluded if they were below 132 
18 years of age, lack of consent, pregnant, had external blunt or penetrating trauma (due to an 133 
external force associated with a motor vehicle crash, fall or assault etc.), had known non-surgical 134 
causes for abdominal pain such as diabetic ketoacidosis, urinary tract infection, gastro-135 
esophageal reflux, or indigestion (dyspepsia), had chronic medical conditions (e.g. inflammatory 136 
bowel disease, cancer, sickle cell anemia), or were taking chronic anti-inflammatory medications. 137 
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 138 
Definition 139 
Acute abdominal pain was defined as pain occurring within 7 days of onset and in an area 140 
extending below the lower ribs, above the inguinal line and between the mid-axillary lines. 141 
Acute appendicitis (AA) was defined as the presence of transmural inflammation of appendix or 142 
the presence of pus in the lumen of the appendix [23]. 143 
Acute appendicitis like syndrome (AALS) is usually characterized by clinical symptoms and 144 
physical examination. Clinical symptoms were classified as typical and atypical. Typical 145 
appendicitis usually included abdominal pain beginning in the region of the umbilicus for several 146 
hours, associated with anorexia, nausea or vomiting. The pain was then localized in the right 147 
lower quadrant, where tenderness developed. Atypical appendicitis lacked this typical 148 
progression and may include pain in the right lower quadrant as an initial symptom. Atypical 149 
appendicitis often requires ultrasound scan and/or CT scan to assist diagnosis.  150 
The Alvarado score is also used for AA diagnosis [24]. The score has 6 clinical items (based on 151 
clinical symptoms and physical examination) and 2 laboratory measurements with a total of 10 152 
points. A score below 5 is strongly against a diagnosis of appendicitis, while a score of 7 or more 153 
is strongly predictive of acute appendicitis. 154 
Healthy controls were defined as age- and sex-matched volunteers with no history of recent 155 
acute illness within 3 months, chronic illness, smoking or medication. 156 
Histologic severity of appendicitis was classified as having no inflammatory features (normal), 157 
foci of neutrophilic infiltration in the wall or mucosa (focal), scattered transmural infiltration 158 
(mild), dense transmural infiltration with tissue distortion (moderate), or dense transmural 159 
infiltration with tissue necrosis or wall perforation (severe) [8]. 160 
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 161 
Data collection and measurable parameters 162 
Using a standardized protocol, an English- and Cantonese-speaking research assistant collected 163 
demographic and previous medical data including age, sex, symptom onset time, time between 164 
sample collection and operative care, medical history (e.g. abdominal pain, seizures, 165 
hypertension, diabetes mellitus, ischaemic heart disease, atrial fibrillation, hyperlipidaemia, 166 
smoking etc.) and current medication.  167 
 168 
Preparation of plasma and RNA extraction 169 
A 10 ml venous blood was taken by standard venipuncture and collected into EDTA-tubes. 170 
Whole blood was collected and stored in TrizolLS (Invitrogen) at -80ºC for further analysis. 171 
Plasma was collected after centrifugation and stored at -80ºC for further analysis of LRG1 172 
protein level. Total RNA was extracted from 400 ul whole blood and has been previously 173 
described [25]. 174 
 175 
One-step  RT-qPCR for LRG1 mRNA and GAPDH mRNA 176 
One-step real-time RT-qPCR was used for measuring the LRG1 mRNA concentrations in the 177 
whole blood RNA samples, based on previously reported methods [25]. The RT-qPCR assay for 178 
LRG1 was developed and optimized. The calibration curve for LRG1 mRNA quantification was 179 
prepared by assaying serial dilutions of HPLC-purified single-stranded synthetic DNA 180 
oligonucleotides (Sigma) specifying a 77-bp LRG1 amplicon, with concentrations ranging from 181 
1 x 107 copies to 1 x 101 copies. The amplification primers were LRG1F 182 
(5'- ACTGCAACCCGCTTAACA -3') and LRG1R (5'- TCCCAAAGTGCTGGGATTAC -3'), 183 
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and the dual-labeled fluorescent probe was LRG1P [5'-(FAM) 184 
AATAATCCTGCCTTTGGCCGGGT (TAMRA)- 3', where FAM is 6-carboxyfluorescein and 185 
TAMRA is 6-carboxytetramethylrhodamine]. For normalization, reference gene, glyceraldehyde 186 
3-phosphate dehydrogenase (GAPDH) mRNA was measured and the assay for GAPDH has also 187 
been well established and described [25]. The concentration of LRG1 and GAPDH mRNA in the 188 
whole blood sample of patients and healthy controls were measured in duplicate. 189 
 190 
ELISA for LRG1 protein analysis  191 
Plasma LRG1 was quantified by human LRG assay (IBL, Fujioka, Japan) according to 192 
manufacturer’s protocols. All samples and reagents were brought to room temperature 30 193 
minutes before use. The level of LRG1 protein in plasma of healthy controls and patients were 194 
measured in duplicate.  195 
 196 
Outcome measures 197 
The primary outcome was the presence or absence of AA. The secondary outcome was the 198 
severity of appendicitis. 199 
 200 
Statistical analysis  201 
Descriptive statistics and data comparison tests (chi-squared, Fisher exact, Mann-Whitney, 202 
Kruskal-Wallis tests), Receiver Operating Characteristic (ROC) analysis, logistic regression, as 203 
well as diagnostic strength were carried out using MedCalc12.3 software (MedCalc Software 204 
bvba). 205 
 206 
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Results  207 
Baseline characteristics  208 
Between 14th December 2011 and 21st October 2012, 84 patients (40 (47.6%) with AA and 44 209 
(52.4%) without AA; median age 35 years; 41.6% males) presenting to the emergency 210 
department with acute abdominal pain of less than seven days duration were recruited.  The 211 
characteristics of the 84 patients are shown in Table 1.  Thirty-one healthy controls, matched for 212 
mean age and sex were also recruited (median age 32 years, 48.4% male). 213 
 214 
Whole Blood LRG1 mRNA and plasma LRG1 in AA diagnosis  215 
Table 2 shows the differentiating features between patients with and patients without AA.  216 
Alvarado score and haematemesis were the only discriminating clinical features.  Median  217 
concentrations of whole blood LRG1 mRNA were significantly different between patients with 218 
and patients without AA (1.3 v 2.2 x105 copies/µl blood; p=0.0134). Median whole blood LRG 219 
mRNA normalized to GAPDH was also significantly different between patients with and patients 220 
without AA (205 v 371 copies/pg GAPDH; p=0.0004). In addition, median plasma LRG1 221 
protein was higher in AA patients than non-AA patients (54 vs 26 mg/l; p<0.0001).  222 
 223 
Figure 1A shows the increase in median LRG1 mRNA concentrations from healthy controls 224 
through non-AA, simple AA to complicated AA (Kruskal-Wallis p<0.0001).  Figure 1B shows 225 
the increase in median LRG mRNA concentrations normalized to GAPDH from healthy controls 226 
through non-AA, simple AA to complicated AA (Kruskal-Wallis P=0.0013).  There are 227 
significant dose-response increases with increasing severity. Figure 1C shows the increase in 228 
median plasma LRG1 concentrations from healthy controls through non-AA, simple AA to 229 
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complicated AA (Kruskal-Wallis P<0.0001). There are significant dose-response increases with 230 
increasing severity. 231 
 232 
Figures 2 shows the receiver operating characteristic (ROC) curves for LRG1 mRNA 233 
concentrations, non-normalized and normalized to GAPDH, plasma LRG1 concentrations, and 234 
combination of LRG1 mRNA and protein concentrations in patients with non- versus AA. The 235 
area under the curve (AUC) of LRG1 mRNA increased from 0.657 to 0.723 after normalization 236 
to GAPDH. When compared to LRG1 mRNA, the plasma LRG1 produced a larger AUC (0.742 237 
vs 0.657). The combination of LRG1 mRNA and plasma LRG1 demonstrated larger AUC (0.743) 238 
(Table 3). In Table 3, combination of LRG1 mRNA (normalized to GAPDH) and protein 239 
demonstrated the larger AUC (0.781). Combination of LRG1 mRNA (normalized to GAPDH), 240 
protein and Alvarado score demonstrated the largest AUC (0.845). 241 
 242 
Table 3 shows the add on effect and accuracy of whole blood combinations of LRG1 mRNA, 243 
LRG1/GAPDH mRNA, plasma LRG1 protein, and Alvarado score for detecting acute 244 
appendicitis. The optimal cut off values for LRG1 mRNA and plasma LRG1 in diagnosis of AA 245 
were 2.0 x105 copies/µl whole blood (sensitivity: 57.5%; specificity: 72.7%) and 31 mg/l 246 
(sensitivity: 77.5%; specificity: 68.2%), respectively. The sensitivity of LRG1 mRNA increased 247 
to 95% after being normalized to GAPDH (cut off: 188 copies/pg GAPDH). Combination of 248 
LRG1/GAPDH mRNA and protein showed the highest sensitivity, which was 97.5%.  249 
 250 
Supplemental Figure 1 shows the receiver operating characteristic (ROC) curves for LRG1 251 
mRNA concentrations, non-normalized and normalized to GAPDH, plasma LRG1 252 
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concentrations, and combination of LRG1 mRNA and protein concentrations in patients with 253 
simple versus complicated AA. The area under the curve (AUC) of LRG1 mRNA, normalized to 254 
GAPDH, protein were 0.694, 0.651 and 0.632 respectively. However, combination of LRG1 255 
mRNA and plasma LRG1 did not improve the diagnostic value (AUC: 0.634) in differentiating 256 
complicated AA from simple AA. Diagnostic accuracy of whole blood combinations of LRG1 257 
mRNA, LRG1/GAPDH mRNA, plasma LRG1 protein, and Alvarado score for discriminating 258 
simple and complicated AA shows on Supplemental Table 1. In differentiation between simple 259 
AA and complicated AA, LRG1 mRNA normalized to GAPDH displayed 100% sensitivity and 260 
33.3% specificity. The sensitivity of LRG1 mRNA and mRNA combined with plasma LRG1 261 
were the same, which was 84.6%, whereas the specificity (63% vs 51.9%) and diagnostic value 262 
(AUC: 0.694 vs 0.634) of LRG1 mRNA alone were higher. 263 
  264 
Factors including LRG1 mRNA, LRG1/GAPDH, LRG1 protein and Alvarado were subjected to 265 
multivariate logistic regression. The logistic regression model for discriminating of acute 266 
appendicitis and complicated AA are shown in Table 4. Results show that whole blood 267 
LRG1/GAPDH mRNA level and Alvarado score are independent predictors of AA. Whole blood 268 
LRG1 mRNA and plasma LRG1 protein predict complicated AA.  269 
 270 
 271 
Discussion  272 
This study shows that normalized and non-normalized whole blood LRG1 mRNA concentrations 273 
measured in patients with acute abdominal pain may be used to differentiate patients with acute 274 
appendicitis from other causes of acute abdomen, and that the highest levels occur in patients 275 
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with complicated gangrenous appendicitis or appendiceal abscess.  These findings raise the 276 
possibility of LRG1 mRNA as a diagnostic marker.   277 
 278 
The diagnosis of acute appendicitis presents a diagnostic challenge to clinicians even when 279 
ultrasound and CT are available. Current laboratory diagnostic markers represent a general 280 
acute-phase reactant response that is not specific for acute appendicitis [36,37].   281 
 282 
The previous discovery that LRG1 protein was elevated in diseased appendices, and also 283 
elevated the blood and urine of children with acute appendicitis, even in the presence of negative 284 
imaging, raised the possibility of a novel diagnostic marker [7]. Further studies showed that the 285 
commercially available LRG1 ELISA was subject to an immunoassay interference effect [8].    286 
 287 
Cellular and circulating proteins are downstream biomarkers in pathological processes and as 288 
such may represent a late feature in disease processes.  Patients presenting with acute conditions 289 
require rapid cellular processes to ‘switch on’ which in turn introduces a delay before biological 290 
abnormalities may appear.  It is likely that upstream changes in such processes produce 291 
molecular changes earlier in acute diseases and may be more useful as early diagnostic and 292 
prognostic markers in disease.  With this rationale we evaluated changes in LRG mRNA 293 
concentrations, the transcriptor for LRG protein, as a potential marker.  The performance of 294 
LRG1 mRNA for the detection of AA was moderate but nevertheless showed a promising dose-295 
response effect. In addition, present study demonstrated that combination of whole blood LRG1 296 
normalized to GAPDH, and its plasma protein level and Alvarado score improve the diagnostic 297 
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accuracy to acute appendicitis, suggesting that LRG1 would have add on effect on Alvarado 298 
score in detecting acute appendicitis.  299 
 300 
The use of a blood based LRG1 mRNA to enhance current clinical decision rules may improve 301 
the accuracy of diagnosing acute appendicitis. An inexpensive but accurate immunoassay could 302 
replace the use of advanced imaging and complex RT-qPCR in patients with equivocal clinical 303 
presentations. LRG1 mRNA is likely to be elevated in clinical scenarios involving bacterial 304 
infections and so its use should be guided by a reasonable clinical suspicion of appendicitis.  305 
 306 
This study is preclinical phase study and limited by the time required for RT-qPCR.  307 
Nevertheless, appropriate commercialisation would allow the possibility of a point of care test.  308 
The study did had a single gold standard for a single condition – acute appendicitis – but it would 309 
be important to evaluate the response of LRG1 mRNA in patients with other causes of 310 
abdominal pain.  Furthermore, LRG1 mRNA offers add on effect on Alvarado score on detecting 311 
acute appendicitis. We had to select out samples for study as we had limited funding but ideally 312 
all samples from consecutive patients would be analyzed.  We have not performed any 313 
comparison with Alvarado score, imaging, or other acute phase proteins so it is unclear whether 314 
LRG1 mRNA offers any advantage over these markers.        315 
 316 
Conclusion  317 
In conclusion, this study shows that both whole blood LRG1 mRNA and plasma LRG1 318 
concentrations are elevated in patients with acute appendicitis and may have a role as a 319 
diagnostic marker.  A combination of modified whole blood LRG1 mRNA levels, serum LRG1 320 
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protein and Alvarado score at the ED may be useful to diagnose AA from other causes of 321 
abdominal pain. 322 
 323 
324 
16 
 
Table 1 Characteristics of 84 patients presenting to hospital with acute abdominal pain and 325 
suspected acute appendicitis  326 
 327 
Characteristics Value 
  
Age 35[16] 18-66 
Sex (male,%) 35 (41.7) 
Day from symptom onset (day) 2 [3] 1-7 
Time of blood collection from arrival of emergency 
department (h) 
11.8 [10.9] 1.7-23.9 
Alvarado 6 [3] 2-10 
Symptoms (no. of patients, %)  
Nausea/vomiting 38 (45.2) 
Haematemesis 0 (0) 
Diarrhoea 19 (22.6) 
Fresh blood in stool 1 (1.2) 
Melaena 1 (1.2) 
Abdominal distension 40 (47.6) 
Poor appetite 53 (63.1) 
Heartburn/Indigestion 7 (8.3) 
Change bowel habit 25 (29.8) 
Jaundice 0 (0) 
Dysuria/urinary frequency 12 (14.3) 
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Syncope/dizziness 29 (34.5) 
Fever 32 (38.1) 
Virginal discharge  3 (3.6) 
Pain feature   
Tenderness RLQ 84 (100) 
Rebound tenderness 35 (41.6) 
Migratory RLQ pain 42 (50) 
Whole blood parameters   
LRG1 mRNA level (x105 copies/µl blood) 1.5 [1.8] 0.24-13.01 
LRG1 mRNA level (copies/pg GAPDH) 300 [288] 78-3818 
GAPDH (pg/µl blood) 567 [390] 6-1856 
Plasma LRG1 protein (mg/l) 39 [40] 4-114 
Type of AA (N = 40)  
Simple AA  27 (67.5%) 
Complicated AA 13 (32.5%) 
  
All continuous data are expressed as medians [interquartile range] and the whole range. 328 
Numbers may not sum up to 100 because of rounding, multiple factors or absent data 329 
 330 
  331 
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Table 2 Comparisons of factors for discriminating acute appendicitis (AA) and non-AA in 84 332 
patients with abdominal pain and suspected AA   333 
 334 
Characteristics Non AA 
(N=44) 
AA 
(N=40) 
p-value 
    
Age 36 [14] 18-58 33 [17] 19-66 0.6412 
Sex (male,%) 14 (31.8) 21 (52.5) 0.0764 
Day from symptom onset (day) 2 [3] 1-7 2 [0] 1-7 0.5424 
Time of blood collection from 
arrival of emergency 
department (h) 
10.8 [12.2] 1.9-23.9 11.8 [9.5] 1.7-22.9 0.5841 
Alvarado 5 [3] 2-8 7 [2] 4-10 <0.0001 
Symptoms (no. of patients, %)    
Nausea/vomiting 20 (45.5) 18 (45) 1.0000 
Haematemesis 0 (0) 0 (0) 0.1013 
Diarrhoea 16 (36. 4) 3 (7.5) 0.0151 
Fresh blood in stool 1 (2.3) 0 (0) 1.0000 
Melaena 1 (2.3) 0 (0) 1.0000 
Abdominal distension 22 (50) 18 (45) 0.3453 
Poor appetite 26 (59.1) 27 (67.5) 0.5000 
Heartburn/Indigestion 5 (11.4) 2 (5) 0.6955 
Change bowel habit 13 (29.5) 12 (30) 0.3163 
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Jaundice 0 (0) 0 (0) 0.1013 
Dysuria/urinary frequency 9 (20.5) 3 (7.5) 0.3411 
Syncope/dizziness 21 (47.7) 8 (20) 0.0894 
Fever 13 (29.5) 19 (47.5) 0.1132 
Virginal discharge  3 (6.8) 0 (0) 0.2770 
Pain feature     
Tenderness RLQ 44 (100) 40 (100) 0.7434 
Rebound tenderness 17 (38.6) 18 (45) 0.6588 
Migratory RLQ pain 15 (34.1) 27 (67.5) 0.2446 
Whole blood parameters     
LRG1 mRNA level (x105 
copies/µl blood)µ 
1.3 [1.5] 0.3-4.3 2.2 [2.3] 0.2-13 0.0134 
LRG1 mRNA level (copies/pg 
GAPDH) 
205 [217] 78-568 371 [232] 149-3818 0.0004 
GAPDH (pg/µl blood) 563 [279] 89-1855 591 [615] 6-1503 0.4572 
Plasma LRG1 level (mg/l) 26 [38] 4-99 54 [40] 55-114 <0.0001 
 335 
All continuous data are expressed as medians [interquartile range] and the whole range. 336 
Categorical variables are given as values (percentages).  337 
P values were derived using the Mann–Whitney test or Fisher exact test as appropriate.  338 
 339 
 340 
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Table 3 Add on effect and accuracy (95% CI) of whole blood combinations of LRG1 mRNA, 341 
LRG1/GAPDH, plasma LRG1 protein, and Alvarado score for detecting acute appendicitis 342 
 Optimal 
cut-off 
AUC Improvement 
in C score* 
Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) 
Alvarado  >5 0.805 
(0.714-0.895) 
- 92.5 
(79.6-98.4) 
56.8 
(41.0-71.7) 
66.1 
(52.2-78.2) 
89.3 
(71.8-97.7) 
LRG1 mRNA  
(x105 copies/ul) 
>2.0 0.657 
(0.538-0.775) 
- 57.5 
(40.9-73.0) 
72.7 
(57.2-85.0) 
65.7 
(47.8-80.9) 
65.3 
(50.4-78.3) 
LRG1/GAPDH 
mRNA 
>188 0.723 
(0.614-0.832) 
0.066  
(10%) 
95.0 
(83.1-99.4) 
47.7 
(32.5-63.3) 
62.3 
(49.0-74.4) 
91.3 
(72.0-99.0) 
LRG1 protein 
(mg/l) 
>31 0.742 
(0.635-0.849) 
0.085  
(13%) 
77.5 
(61.6-89.2) 
68.2 
(52.4-81.4) 
68.9 
(53.4-81.8) 
76.9 
(60.7-88.9) 
LRG1 mRNA + 
plasma LRG1 protein 
>12.4 0.743 
(0.636-0.850) 
0.086  
(13%) 
77.5 
(61.5-89.2) 
68.2 
(61.5-89.2) 
68.9 
(53.4-81.8) 
76.9 
(60.7-88.9) 
LRG1/GAPDH 
mRNA + LRG1 
protein 
>1.7 0.781 
(0.663-0.879) 
0.124  
(19%) 
97.5 
(86.8-99.9) 
50 
(34.6-65.4) 
63.9 
(50.6-75.4) 
95.7 
(78.1-99.9) 
Alvarado + 
LRG1/GAPDH 
mRNA +LRG1 
protein  
>5.6 0.845 
(0.764-0.925) 
0.188  
(29%) 
87.5 
(73.2-95.8) 
65.9 
(50.1-79.5) 
70 
(53.4-58.8) 
85.3 
(68.9-95.1) 
*  from LRG1 mRNA  343 
 344 
 345 
  346 
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Table 4 Logistic regression model of factors for discriminating acute appendicitis (AA) and 347 
complicated AA  348 
 Before stepwise   After stepwise 
Factor Adjusted Odds ratio 
(95%CI) 
P value  Adjusted Odds ratio 
(95%CI) 
P value 
AA vs non AA       
Whole blood LRG1 mRNA * 0.83 (0.23-2.97) 
 
0.7746    
Whole blood LRG1/GAPDH 
mRNA * 
18.76 (3.27-107.62) 0.0010  16.50 (3.10-87.71) 0.0010 
Plasma LRG1 protein * 2.70 (0.74-9.81) 0.1322    
Alvarado 2.00 (1.22-3.13) 0.0052  2.22 (1.46-3.37) 0.0002 
      
Complicated AA vs simple AA       
Whole blood LRG1 mRNA * 7.26 (0.78-66.86) 0.0814  9.72 (1.60-59.12) 0.0136 
Whole blood LRG1/GAPDH 
mRNA * 
2.27 x 106  0.9940    
Plasma LRG1 protein * 6.94 (0.85-56.65) 0.0705  5.93 (1.11-31.60) 0.0371 
Alvarado 0.81 (0.36-1.85) 
 
0.6220    
               * Optimal cut-off  349 
 350 
 351 
 352 
 353 
 354 
 355 
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Figures 356 
Figure 1. Box-plot of median level of (A) whole blood LRG1 mRNA (B) LRG1/GAPDH mRNA 357 
and (C) plasma LRG1 protein of healthy controls (HC), non acute appendicitis patients (nonAA), 358 
patients with simple AA and patients with complicated AA.   359 
 360 
 361 
Figure 2 Receiver operating characteristic (ROC) curves of whole blood LRG1 mRNA, 362 
LRG1/GAPDH mRNA, plasma LRG1 concentrations, combination of LRG1 mRNA and protein 363 
concentrations, combination of LRG1/GAPDH mRNA and LRG1 protein concentrations, and 364 
combination of Alvarado (Alv), LRG1/GAPDH mRNA, LRG1 protein concentrations in patients 365 
with AA versus non-AA.  366 
 367 
Figure 1A  368 
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 370 
Figure 1B  371 
 372 
Figure 1C  373 
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Figure 2 375 
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Appendix 1 481 
 482 
 Sensitivity Specificity  Accuracy  
Plain x-ray 50% 50%  
US 
(Inexperienced) 
75% 86% 80% 
ED Physicians 80% 84%  
Alvarado <6 94% 80% 90% 
US 
(Experienced) 
90% 100% 96% 
CT scan 96 – 100% 95 – 97% 96 – 98% 
MRI 100% 94%  
 483 
 484 
  485 
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Supplemental Table 1 Accuracy (95% CI) of whole blood LRG1 mRNA, whole blood LRG1 486 
/GPADH mRNA, plasma LRG1 protein, Alvarado,  combination of whole blood LRG1 mRNA 487 
and  plasma LRG1 protein, combination of whole blood LRG1/GAPDH mRNA and  plasma 488 
LRG1 protein Alvarado, and combination of Alvarado, whole blood LRG1/GAPDH mRNA and 489 
plasma LRG1 protein for discriminating complicated acute appendicitis 490 
 Optimal 
cut-off 
AUC Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) PLR (%) NLR (%) 
Alvarado  >6 0.655 
(0.482-0.828) 
84.6 
(54.6-
98.1) 
40.7 
(22.4-61.2) 
40.7 
(22.4-61.2) 
84.6 
(54.6-98.1) 
1.43 
(0.97-2.11) 
0.38 
(0.1-1.46) 
LRG1 mRNA  
(x105 copies/ul) 
>2.1 0.694 
(0.518-0.870) 
84.6 
(54.6-
98.1) 
63.0 
(42.4-80.6) 
52.4 
(29.8-74.3) 
89.5 
(66.7-98.7) 
2.28 
(1.33-3.93) 
0.24 
(0.07-0.90) 
LRG1 /GAPDH 
mRNA 
>261 0.651 
(0.477-0.825) 
100 
(75.3-100) 
33.3 
(16.5-54.0) 
41.9 
(24.6-60.9) 
100 
(66.4-100) 
1.50 
(1.15-1.96) 
0.00 
LRG1 protein 
(mg/l) 
>55 0.632 
(0.436-0.829) 
76.9 
(46.2-
95.0) 
63.0 
(42.4-80.6) 
50.0 
(27.2-72.8) 
85.0 
(62.1-96.8) 
2.08 
(1.17-3.69) 
0.37 
(0.13-1.03) 
Whole blood 
LRG1 mRNA + 
plasma LRG1 
protein 
>0.9 0.634 
(0.453-0.814) 
84.6 
(54.6-
98.1) 
51.9 
(31.9-71.3) 
45.8 
(25.6-67.2) 
87.5 
(61.7-98.5) 
1.76 
(1.12-2.77) 
0.30 
(0.08-1.12) 
Whole blood 
LRG1/GAPDH 
mRNA + plasma 
LRG1 protein 
>0.7 0.652 
(0.453-0.852) 
84.6 
(54.6-
98.1) 
59.3 
(38.8-77.6) 
50 
(28.2-71.8) 
88.9 
(65.3-98.6) 
2.08 
(1.25-3.46) 
0.72 
(0.56-0.85) 
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 491 
 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
Alvarado + 
Whole blood 
LRG1/GAPDH 
mRNA + plasma 
LRG1 protein  
>3.1 0.685 
(0.521-0.850) 
92.3 
(64.0-
99.8) 
44.4 
(25.5-64.7) 
44.4 
(25.5-64.7) 
92.3 
(64.0-99.8) 
1.66 
(1.15-2.41) 
0.68 
(0.52-0.82) 
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Supplemental Figure 1 Receiver operating characteristic (ROC) curves for whole blood LRG1 510 
mRNA concentrations, whole blood LRG1 mRNA normalized to GAPDH, plasma LRG1 511 
concentrations, combination of LRG1 mRNA and protein concentrations,  combination of LRG1 512 
mRNA normalized to GAPDH and protein concentrations, and combination of Alvarardo (Alv), 513 
LRG1 mRNA normalized to GAPDH, protine concentration in patients simple versus 514 
complicated AA  515 
 516 
 517 
 518 
 519 
 520 
0
20
40
60
80
100
0 20 40 60 80 100
100-Specificity
Se
ns
iti
v
ity
LRG1 mRNA (AUC: 0.694)
LRG1/GAPDH (AUC: 0.651)
LRG1 protein (AUC: 0.632)
LRG1 mRNA + LRG1 protein (AUC: 0.634)
LRG1 /GAPDH + LRG1 protein (AUC: 0.0.652)
Alv + LRG1 /GAPDH + LRG1 protein (AUC: 0.685)
34 
 
Supplemental Figure 2 Temporal changes in (A) LRG1 mRNA, (B) LRG1 mRNA normalized 521 
to GAPDH, (C) and plasma LRG1 from symptom onset (days) to blood sampling for the AA and 522 
non-AA groups. Data is presented as the mean ± SEM. Significant difference  in LRG1 mRNA 523 
or plasma LRG1 was found between AA and non-AA patient with P<0.05 by using t-test (*). 524 
 525 
Supplemental Figure 2A 526 
 527 
Supplemental Figure 2B 528 
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 530 
 531 
Supplemental Figure 2C 532 
 533 
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